Kazia Therapeutics Limited
KZIA
$6.75
$0.172.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | 18,900.00% | 18,866.67% | -- |
| Total Revenue | -- | -- | 272,400.00% | 271,833.33% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 272,400.00% | 271,833.33% | -- |
| SG&A Expenses | 12.13% | 14.74% | 106.33% | 101.24% | 5.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.70% | 8.17% | 107.05% | 101.94% | -35.45% |
| Operating Income | -5.45% | -7.91% | -83.78% | -79.24% | 35.45% |
| Income Before Tax | -18.18% | -20.95% | -154.42% | -148.13% | 35.30% |
| Income Tax Expenses | 0.00% | -2.25% | 1.33% | 3.89% | 0.90% |
| Earnings from Continuing Operations | -18.46% | -21.23% | -157.48% | -151.13% | 35.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.46% | -21.23% | -157.48% | -151.13% | 35.64% |
| EBIT | -5.45% | -7.91% | -83.78% | -79.24% | 35.45% |
| EBITDA | -6.09% | -8.57% | -92.09% | -87.35% | 37.99% |
| EPS Basic | 33.19% | 31.63% | -99.58% | -94.66% | 60.90% |
| Normalized Basic EPS | 27.27% | 25.57% | -33.98% | -30.67% | 61.19% |
| EPS Diluted | 33.19% | 31.63% | -99.58% | -94.65% | 60.90% |
| Normalized Diluted EPS | 27.27% | 25.57% | -33.98% | -30.67% | 61.19% |
| Average Basic Shares Outstanding | 77.29% | 77.29% | 29.00% | 29.00% | 64.64% |
| Average Diluted Shares Outstanding | 88.89% | 88.89% | 37.50% | 37.50% | 80.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |